Nordic Bioproducts Group

Commercialises Aalto University's AaltoCell™ process for microcrystalline cellulose (MCC) used as a pharmaceutical excipient and in food and cosmetics. Aalto spin-off founded in 2019 by Professor Olli Dahl with Olli Kähkönen and the Aalto School of Chemical Engineering. Opened a commercial-scale continuous-process plant in Lappeenranta in 2024 — production is running, which sets it apart from most early-stage materials rows. Oji Holdings (Japan) holds 20% since 1/2026; supply partnerships in Southern Europe.

The row

Sector

Advanced Materials

Stage

In market — Product is being sold

Location

Espoo

Founded

2019

Research origin

Aalto

Business ID

3006967-4 · Finnish trade register

Funding

Strategic minority investment: Oji Holdings (Japan) took a 20% stake in 1/2026; amount not disclosed

Links

Where this sits on the map

Nordic Bioproducts Group is one of 16 companies in Advanced Materials. The others:

How this row was decided

Every row on this map is checked by hand against the trade register and the company's own material, and placed in the sector that best describes its business or its technology. Service firms and consultancies are left out, however advanced the technology they work with — the test is where the revenue comes from. Only funding figures the company or its investor has published are shown. The full rules are on the landscape ↗